- ►jcojournal.org [PDF] P Bonomi, JA Blessing, FB Stehman, PJ DiSaia … - Journal of Clinical Oncology, 1985 - jcojournal.org The Gynecologic Oncology Group has conducted a randomized prospective trial
comparing cisplatin 50 mg/m 2 every 21 days (regimen 1), 100 mg/m2 every 21 days
(regimen 2), and cisplatin 20 mg/m 2 for five consecutive days repeated ... Cited by 235 - Related articles - All 6 versions
NK Kim, YS Park, DS Heo, C Suh, SY Kim, KC … - CA A Cancer Journal for Clinicians - interscience.wiley.com Background. With the introduction of cisplatincontaining regimens in the
treatment of advanced gastric cancer, promising clinical results have been
reported. A 61.5% response rate was observed with a combination of 5- ... Cited by 217 - Related articles - BL Direct - All 3 versions
- ►aacrjournals.org [PDF] GA Curt, JJ Grygiel, BJ Corden, RF Ozols, RB … - Cancer Research, 1983 - AACR ABSTRACT Carboplatin (CBDCA; NSC 241240) ¡sa second-generation platinum
coordination compound which in preclinical testing was found to be less
nephrotoxic and emetogenic than c/s-diam- minedichloroplatinum (CDDP), ... Cited by 117 - Related articles - All 3 versions
R Baliga, Z Zhang, M Baliga, N Ueda, SV … - Kidney international, 1998 - nature.com In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced
nephrotoxicity. Cisplatin is a widely used antineoplastic agent that has
nephrotoxicity as a major side effect. The underlying mechanism of this ... Cited by 109 - Related articles - BL Direct - All 4 versions
- ►jcojournal.org [PDF] WK Yung, L Mechtler, MJ Gleason - Journal of Clinical Oncology, 1991 - jcojournal.org Thirty patients with recurrent malignant glioma were treated with intravenous
(IV) carboplatin (CBDCA) every 4 weeks at a starting dose of 400 mg/m2
escalating to 450 mg/m'. All patients had documented recurrent tumor after ... Cited by 107 - Related articles - All 7 versions
TJ Walsh, AW Clark, IM Parhad, WR Green - Archives of Neurology, 1982 - archneur.highwire.org \s=b\Swelling of the optic disc and loss of tendon reflexes developed in a
31/2-year- old girl after 11 high-dose courses of cisplatin
(cis-dichlorodiammine platinum [II]) therapy for recurrent sacrococcygeal ... Cited by 100 - Related articles - All 4 versions
GP Kaushal, V Kaushal, X Hong, SV Shah - Kidney international, 2001 - nature.com Cellular and molecular mechanisms responsible for cisplatin-induced
nephrotoxicity to renal tubular epithelial cells are not well understood.
Although caspases play a critical role in the execution of the cell death ... Cited by 91 - Related articles - BL Direct - All 4 versions
NJ Vogelzang, JL Torkelson, BJ Kennedy - CA A Cancer Journal for Clinicians - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 90 - Related articles - All 3 versions
E Gianasi, M Wasil, EG Evagorou, A Keddle, … - European Journal of Cancer, 1999 - Elsevier The aim of this study was to compare in vitro and in vivo HPMA copolymer
platinates with cisplatin in terms of platinum release, toxicity and antitumour
activity. N-(2-hydroxypropyl)methacrylamide (HPMA) conjugates containing ... Cited by 87 - Related articles - BL Direct - All 8 versions
- ►jbc.org R Seth, C Yang, V Kaushal, SV Shah, GP … - Journal of Biological Chemistry, 2005 - ASBMB We demonstrate the role of p53-mediated caspase-2 activation in the
mitochondrial release of apoptosis-inducing factor (AIF) in cisplatin-treated
renal tubular epithelial cells. Gene silencing of AIF with its small ... Cited by 76 - Related articles - BL Direct - All 5 versions
